MedPath
Found 14 clinical trials|View Analysis
Sort by:

Role of Ajwa Derived Polyphenols in Dyslipidaemias

Not Applicable
Conditions
Oxidative Stress
Liver Dysfunction
Hemoglobin SC
Dyslipidemias
Hyperglycemia
Anemia
Interventions
Dietary Supplement: Ajwa Date (phoenix dactylifera)
First Posted Date
2019-01-15
Last Posted Date
2019-11-12
Lead Sponsor
Aga Khan University
Target Recruit Count
60
Registration Number
NCT03805139
Locations
🇵🇰

Aga Khan University, Karachi, Sindh, Pakistan

Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias

Recruiting
Conditions
Patient With Dyslipidemia
Interventions
Other: Detection of patients with dyslipidemia
First Posted Date
2018-02-28
Last Posted Date
2022-07-05
Lead Sponsor
University Hospital, Montpellier
Target Recruit Count
977
Registration Number
NCT03449784
Locations
🇫🇷

Uhmontpellier, Montpellier, France

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Phase 2
Completed
Conditions
Dyslipidemias
Dyslipidaemias
Interventions
Drug: 10mg atorvastatin
Drug: GSK1292263 Placebo
Drug: 80mg atorvastatin
Other: Washout
Drug: 300mg GSK1292263
Drug: 100mg GSK1292263
Drug: 800mg GSK1292263
Drug: 10mg ezetimibe
First Posted Date
2010-10-11
Last Posted Date
2019-07-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
287
Registration Number
NCT01218204
Locations
🇺🇸

GSK Investigational Site, Renton, Washington, United States

Study to Test GSK256073 in Patients With Dyslipidemia

Phase 2
Completed
Conditions
Dyslipidaemias
Dyslipidemias
Interventions
Drug: Placebo
Drug: Niaspan
Drug: GSK256073
First Posted Date
2009-05-18
Last Posted Date
2019-12-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
80
Registration Number
NCT00903617
Locations
🇺🇸

GSK Investigational Site, Seattle, Washington, United States

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

Phase 1
Completed
Conditions
Dyslipidaemias
Interventions
Drug: GSK256073
First Posted Date
2008-12-15
Last Posted Date
2017-06-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
30
Registration Number
NCT00808093
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Phase 1
Completed
Conditions
Dyslipidaemias
Interventions
Drug: an undetermined dose of GSK1292263
Drug: ascending dose of GSK1292263
First Posted Date
2008-10-31
Last Posted Date
2017-07-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
76
Registration Number
NCT00783549
Locations
🇺🇸

GSK Investigational Site, Minneapolis, Minnesota, United States

A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Subjects
Dyslipidaemias
First Posted Date
2008-02-06
Last Posted Date
2012-04-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
24
Registration Number
NCT00608699
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

A Second Study to Determine the Effect of GSK256073A on HVTs

Phase 1
Completed
Conditions
Healthy Subjects
Dyslipidaemias
First Posted Date
2007-10-31
Last Posted Date
2012-06-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
4
Registration Number
NCT00551694
Locations
🇺🇸

GSK Investigational Site, Minneapolis, Minnesota, United States

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

Phase 1
Completed
Conditions
Dyslipidaemias
Healthy Subjects
First Posted Date
2007-06-20
Last Posted Date
2012-06-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
56
Registration Number
NCT00488449
Locations
🇺🇸

GSK Investigational Site, Baltimore, Maryland, United States

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Phase 2
Completed
Conditions
Healthy Subjects
Dyslipidaemias
Dyslipidaemia
First Posted Date
2007-05-17
Last Posted Date
2012-06-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
66
Registration Number
NCT00474864
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath